Seer (SEER) Total Liabilities (2020 - 2026)
Seer (SEER) posted quarterly Total Liabilities of $30.7 million for Q1 2026, down 15.45% year-over-year from $36.3 million in Q1 2025, and down 16.65% quarter-over-quarter from $36.8 million in Q4 2025.
Analysis
Seer (SEER) Total Liabilities (2020 - 2026) Analysis & Trends
Seer's Total Liabilities history runs 7 years deep, the most recent figure standing at $30.7 million for Q1 2026.
- In Q1 2026, Total Liabilities fell 15.45% year-over-year to $30.7 million; the TTM figure through Mar 2026 stood at $30.7 million (down 15.45% YoY), while the FY2025 annual figure was $36.8 million, down 5.77% from the prior year.
- Total Liabilities for Q1 2026 stood at $30.7 million, down from $36.8 million in the prior quarter.
- The five-year high for Total Liabilities was $44.3 million in Q2 2022, with the low at $30.7 million in Q1 2026.
- The 5-year median for Total Liabilities is $39.2 million (2023), against an average of $39.0 million.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities jumped 311.66% in 2022, then declined 18.41% in 2025.
- Seer's Total Liabilities stood at $40.9 million in 2022, then retreated by 3.84% to $39.4 million in 2023, then retreated by 0.86% to $39.0 million in 2024, then dropped by 5.77% to $36.8 million in 2025, then fell by 16.65% to $30.7 million in 2026.
- Business Quant data shows SEER's Total Liabilities at $30.7 million in Q1 2026, $36.8 million in Q4 2025, and $36.8 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 4.20 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.72 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 4.00 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 10.03 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Seer | 107.57 Mn | 107.57 Mn | 1.51 Mn | 30.96 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 30.96 Mn |
| Mar 31, 2026 | 30.65 Mn |
| Dec 31, 2025 | 36.78 Mn |
| Sep 30, 2025 | 36.79 Mn |
| Jun 30, 2025 | 34.20 Mn |
| Mar 31, 2025 | 36.26 Mn |
| Dec 31, 2024 | 39.03 Mn |
| Sep 30, 2024 | 38.70 Mn |
| Jun 30, 2024 | 41.91 Mn |
| Mar 31, 2024 | 38.41 Mn |
| Dec 31, 2023 | 39.37 Mn |
| Sep 30, 2023 | 39.17 Mn |
| Jun 30, 2023 | 43.08 Mn |
| Mar 31, 2023 | 39.80 Mn |
| Dec 31, 2022 | 40.94 Mn |
| Sep 30, 2022 | 42.44 Mn |
| Jun 30, 2022 | 44.26 Mn |
| Mar 31, 2022 | 40.63 Mn |
| Dec 31, 2021 | 36.22 Mn |
| Sep 30, 2021 | 12.64 Mn |